mitomycin has been researched along with ellagic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Bartolini, F; Cozzi, R; De Salvia, R; Perticone, P; Ramadori, L; Ricordy, R | 1 |
| Atzori, MG; Bonanno, E; Ceci, C; Cicconi, R; de Martino, MG; Graziani, G; Lacal, PM; Mattei, M; Miano, R; Scimeca, M; Tentori, L; Vespasiani, G | 1 |
3 other study(ies) available for mitomycin and ellagic acid
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Taurine and ellagic acid: two differently-acting natural antioxidants.
Topics: Animals; Antimutagenic Agents; Antioxidants; CHO Cells; Chromosome Aberrations; Cricetinae; Ellagic Acid; Flow Cytometry; Hydrogen Peroxide; Mitomycin; Mutagenicity Tests; Mutagens; Sister Chromatid Exchange; Taurine | 1995 |
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-H1 Antigen; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Ellagic Acid; Humans; Inhibitory Concentration 50; Male; Mice, Nude; Mitomycin; Neoplasm Invasiveness; Neovascularization, Pathologic; Signal Transduction; Time Factors; Tumor Burden; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2016 |